1532 A phase 1/2 study of safety, tolerability, and pharmacokinetics of SNS-101, a pH-sensitive anti-VISTA mAb, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors

• Kyriakos Papadopoulos,
• Shiraj Sen,
• Justin Call,
• FD Smith,
• Edward H van der Horst

Affiliations

Kyriakos Papadopoulos

3START San Antonio, San Antonio, TX, USA

Shiraj Sen

1NEXT Oncology, Irving, TX, USA

Justin Call

2START Mountain Region, West Valley City, UT, USA

FD Smith

4Sensei Biotherapeutics, Boston, MA, USA

Edward H van der Horst

4Sensei Biotherapeutics, Boston, MA, USA